NCT05500222Phase 3Active not recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants845Estimated

Source updated2026-07-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-02 · 1 field changed

Enrollment · participant count

Recorded edit

− Previous value

count: 700; type: ESTIMATED

+ Updated value

count: 845; type: ESTIMATED

Check registry source

Study details

Conditions studied

NASH; Cirrhosis, Liver

Treatments or interventions studied

ResmetiromDrugAlso known as MGL-3196
PlaceboDrug

Primary outcomes · main study measures

measure: Incidence Of adjudicated Composite Clinical Outcome event; description: Any event of all-cause mortality, liver transplant, ascites, hepatic encephalopathy, gastroesophageal variceal hemorrhage, and confirmed increase of MELD score from \<12 to \>/= 15 due to liver disease; timeFrame: Baseline up to Month 36

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history